Pharma BD Deal Intelligence

Celgene Corporation / Abraxis BioScience Inc.

2010 · Acquisition/Merger · $2.9B · Complete

Announcement Sentiment

Positive

Celgene agreed to buy Abraxis BioScience for $2.9B in cash and stock plus tradeable CVR for future milestones/royalties. Each share received $58.00 cash + 0.2617 Celgene shares + 1 CVR.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Jun 30, 2010
Closed Oct 15, 2010
Deal value $2.9B
Deal type Acquisition/Merger
Therapeutic area Breast cancer; pancreatic cancer; NSCLC
Indications Breast cancer; pancreatic cancer; NSCLC
Key assets Abraxane (nab-paclitaxel)
Mechanism Albumin-bound paclitaxel formulation

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals